Efficacy of Formulated Posterior Sub Tenon Triamcinolone in Macular Edema Secondary to Non-Ischemic Retinal Vein Occlusions

Al-Azhar University

Status: Completed

Conditions: Retinal Vein Occlusion

Treatments: Drug: Triamcinolone Acetonide

Study type: Interventional

Funder types: Other

Identifiers

NCT05345808

PSTA in macular edema

Details and patient eligibility

About

Retinal vein occlusion (RVO) is considered the second vascular disorder of the retina after diabetic retinopathy. Patients with RVO are at risk of the development of macular edema. Different treatment modalities for macular edema include LASER therapy, antivascular endothelial growth factor (VEGF), and triamcinolone.

Aim To detect the efficacy of formulated Triamcinolone Acetonide(TA) injection in the posterior subtenon space to manage macular edema secondary to non-ischemic RVOs, either central or branch.

Enrollment: 46 patients

Sex: All

Ages: 50 to 69 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diminution of vision due to macular edema secondary to non-ischemic retinal vein occlusions, either central or branch
• CMT ≥ 250 µ,
• Willing to participate in the study.

Exclusion criteria

• Unwilling to participate in the study
• Ischemic RVO
• previous laser treatment
• Glaucoma, macular ischemia, cataract, vitreous hemorrhage, and neovascularization of the iris
• patients with previous anti VEGFs or steroid injections or any eye surgery three months before the inclusion
• Cardiac co-morbidities result in significant hemodynamic changes
• Respiratory diseases need treatment with antibiotics
• Suffering from other chronic diseases as diabetes
• Patient with allergy from triamcinolone acetonide.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

46 participants in 1 patient group

Formulated Posterior Sub Tenon Triamcinolone

Other group

Description:

All the eyes received single dose 40 mg of Triamcinolone Acetonide (TA) and VISCOAT which is 20 mg sodium chondroitin sulphate and 15 mg sodium hyaluronate (0.5 ml) through posterior subtenon route using NAGATA subtenon canula.

Treatment:

Drug: Triamcinolone Acetonide